A new study on the effects of the Dengvaxia vaccine provides basis to demand a full refund of the P3-billion anti-dengue program, a lawmaker said on Monday.
“Sanofi has rejected DOH’s (Department of Health) request for a full refund multiple times now, refusing to pay the Philippine government back for the vaccines already used. The Philippines through the DOH has more leverage than ever to seek the refund,” House Appropriation committee chair Karlo Alexei B. Nograles said in a statement.
The study of the New England Journal of Medicine further validated the World Health Organization’s (WHO) findings that the vaccine poses increased risk, if inoculated to children who have never contracted dengue.
“The published findings confirmed Sanofi’s belated admission of the pitfalls of Dengvaxia. It also upheld the World Health Organization recommendation last April that the vaccine should not be used without testing for prior dengue exposure,” Mr. Nograles said. — Charmaine A. Tadalan

RELATED ARTICLESMORE FROM AUTHOR